Carlos Fernando Mendoza
Research Subjects
Research Interests
Carlos Fernando Mendoza has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Julia Spinardi
Vaccines Medical Affairs, Pfizer Inc., São Paulo 04717-904, Brazil
3 shared publications - Moe Hein Kyaw
Pfizer Inc., New York, NY 10001, USA
3 shared publications Ben Yarnoff
PPD Evidera Health Economics and Market Access, Thermo Fisher Scientific, Waltham, MA, USA
2 shared publicationsIustina Chirila
Pfizer Ltd., Tadworth, UK
2 shared publications- Jingyan Yang
Pfizer Inc., New York, United States
2 shared publications - Ana Carolina Dantas
Vaccines, Medical, Pfizer Inc., Buenos Aires City C1437, Argentina
1 shared publication
Latest Publications
- Open Access
- 3 July 2026
- Published by Springer Nature in Pulmonary Therapy
- Vol. 12 (3) , 905-915
Estimating the Underreporting of COVID-19 Burden in Selected Countries in Asia, Africa, the Middle East, and Latin America in the Post-pandemic Era
The true number of coronavirus disease-19 (COVID-19) cases may be highly underestimated because of reduced efforts to track cases through testing in the postpandemic era. Earlier estimates of this underreporting have varied across regions, and countries in Asia, Africa, the Middle East, and Latin America have been notably impacted. This study investigates the true burden of COVID-19 cases in 2023 and 2024 across Asia, Africa, the Middle East, and Latin America. We conducted a retrospective analysis of national public health surveillance data from 2022 to 2024 on COVID-19 cases, hospitalizations, and deaths in Asia, Africa, the Middle East, and Latin America. Using a method developed by the US Centers for Disease Control and Prevention to estimate the burden of COVID-19 and influenza, we estimated the number of cases for 2023 and 2024 by calculating the ratio of cases to hospitalization and cases to deaths, using 2022 as the baseline. We compared the estimated and reported number of cases each year to assess the level of underreporting. The mean ratio of estimated cases to reported cases showed a high albeit variable level of underreporting in 2023 and 2024 across regions. In 2023, the levels of underreported cases were 1295%, 319%, 560%, and 3703% in Asia, the Middle East, Latin America, and Africa, respectively. The number of estimated underreported cases generally increased in 2024 to 2326%, 1415% and 16,664% in Asia, Latin America, and Africa, respectively, but in the Middle East decreased to 87% based on hospitalization data. The trend for death data was similar. The results highlight the high level of underreporting of COVID-19 cases, which has increased over time in many regions. Therefore, the true global burden of COVID-19 could be substantially higher than indicated by publicly available data. Continued COVID-19 surveillance is crucial for stabilizing public health measures such as prevention and target vaccination programs.
- 3 July 2026
- Published by Springer Nature in Pulmonary Therapy
- Vol. 12 (3) , 905-915
Open AccessEstimating the Underreporting of COVID-19 Burden in Selected Countries in Asia, Africa, the Middle East, and Latin America in the Post-pandemic Era
The true number of coronavirus disease-19 (COVID-19) cases may be highly underestimated because of reduced efforts to track cases through testing in the postpandemic era. Earlier estimates of this underreporting have varied across regions, and countries in Asia, Africa, the Middle East, and Latin America have been notably impacted. This study investigates the true burden of COVID-19 cases in 2023 and 2024 across Asia, Africa, the Middle East, and Latin America. We conducted a retrospective analysis of national public health surveillance data from 2022 to 2024 on COVID-19 cases, hospitalizations, and deaths in Asia, Africa, the Middle East, and Latin America. Using a method developed by the US Centers for Disease Control and Prevention to estimate the burden of COVID-19 and influenza, we estimated the number of cases for 2023 and 2024 by calculating the ratio of cases to hospitalization and cases to deaths, using 2022 as the baseline. We compared the estimated and reported number of cases each year to assess the level of underreporting. The mean ratio of estimated cases to reported cases showed a high albeit variable level of underreporting in 2023 and 2024 across regions. In 2023, the levels of underreported cases were 1295%, 319%, 560%, and 3703% in Asia, the Middle East, Latin America, and Africa, respectively. The number of estimated underreported cases generally increased in 2024 to 2326%, 1415% and 16,664% in Asia, Latin America, and Africa, respectively, but in the Middle East decreased to 87% based on hospitalization data. The trend for death data was similar. The results highlight the high level of underreporting of COVID-19 cases, which has increased over time in many regions. Therefore, the true global burden of COVID-19 could be substantially higher than indicated by publicly available data. Continued COVID-19 surveillance is crucial for stabilizing public health measures such as prevention and target vaccination programs.
- Open Access
- 14 May 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1) , 2668675
Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in Guatemala
1. As of 21 December 2024, SARS-CoV-2, the virus that causes for COVID-19, has resulted in approximately 777 million cases and seven million deaths globally, with about 1.3 million cases and 20,200...
- 14 May 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1) , 2668675
Open AccessModeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in Guatemala
1. As of 21 December 2024, SARS-CoV-2, the virus that causes for COVID-19, has resulted in approximately 777 million cases and seven million deaths globally, with about 1.3 million cases and 20,200...
- Open Access
- 22 May 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 10 (6) , 146
Burden in Colombia of COVID-19 in Adults and the Associated Clinical Characteristics: A Retrospective Database Analysis
Studies on the burden of COVID-19 cases in Colombia have focused on specific populations and short timeframes. A retrospective observational study was conducted on adult patients aged 18 diagnosed with COVID-19 who received inpatient and/or outpatient medical care at a large health maintenance organization, to evaluate the burden of COVID-19 cases in Colombia (from March 2020 to January 2023) and associations with demographic and clinical characteristics. COVID-19 cases were identified with ICD-10 codes and confirmed by a laboratory test. The statistical analysis focused on descriptors of the frequency of events. A multivariate regression model was used to identify factors associated with severe conditions and death. Of the 953,661 cases detected, most cases (~79%) were mild or moderate (handled as outpatients). There were 20.1% (N = 191,260) severe cases and 0.9% (N = 8841) critical cases. Most COVID patients were unvaccinated (94.6%) and had, on average, one comorbidity. Hypertension (19.1%), immunocompromised condition (23.8%), mental health conditions (15%), obesity (10.8%), and cancer (11.2%) were the common prevalent comorbidities. The presence of comorbidity increased the risk of severe or critical COVID-19. COVID-19 cases were associated with the lack of vaccination and comorbidities. Effective vaccination strategies are needed to reduce the burden of COVID-19 in Colombia and, considering budgetary constraints, it is advisable to prioritize the elderly or populations with underlying conditions.
- 22 May 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 10 (6) , 146
Open AccessBurden in Colombia of COVID-19 in Adults and the Associated Clinical Characteristics: A Retrospective Database Analysis
Studies on the burden of COVID-19 cases in Colombia have focused on specific populations and short timeframes. A retrospective observational study was conducted on adult patients aged 18 diagnosed with COVID-19 who received inpatient and/or outpatient medical care at a large health maintenance organization, to evaluate the burden of COVID-19 cases in Colombia (from March 2020 to January 2023) and associations with demographic and clinical characteristics. COVID-19 cases were identified with ICD-10 codes and confirmed by a laboratory test. The statistical analysis focused on descriptors of the frequency of events. A multivariate regression model was used to identify factors associated with severe conditions and death. Of the 953,661 cases detected, most cases (~79%) were mild or moderate (handled as outpatients). There were 20.1% (N = 191,260) severe cases and 0.9% (N = 8841) critical cases. Most COVID patients were unvaccinated (94.6%) and had, on average, one comorbidity. Hypertension (19.1%), immunocompromised condition (23.8%), mental health conditions (15%), obesity (10.8%), and cancer (11.2%) were the common prevalent comorbidities. The presence of comorbidity increased the risk of severe or critical COVID-19. COVID-19 cases were associated with the lack of vaccination and comorbidities. Effective vaccination strategies are needed to reduce the burden of COVID-19 in Colombia and, considering budgetary constraints, it is advisable to prioritize the elderly or populations with underlying conditions.
- Open Access
- 24 April 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (5) , 669
COVID-19 Disease and Economic Burden to Healthcare Systems in Adults in Six Latin American Countries Before Nationwide Vaccination Program: Ministry of Health Database Assessment and Literature Review
The COVID-19 pandemic imposed a substantial burden on healthcare systems worldwide, yet reliable data on COVID-19 morbidity, mortality, and healthcare costs in Latin America remain limited. This study explored the disease and economic burden of COVID-19 in Argentina, Brazil, Chile, Colombia, Mexico, and Peru during the pre-vaccination period. Using national databases and a systematic review of the literature, we analyzed data on adults aged 18 and older, reporting cases, death rates, years of life lost, excess mortality, and direct medical costs. Before vaccination programs began, the average COVID-19 incidence rate was 6741 per 100,000 adults. Of these, 91% were mild cases, 7% moderate/severe, and 2% critical. Among 2,201,816 hospitalizations, 27.8% required intensive care, and 17.5% required mechanical ventilation. Excess mortality ranged from 76 to 557 per 100,000, and years of life lost spanned 241,089 to 3,312,346. Direct medical costs ranged from USD 258 million to USD 10,437 million, representing 2–5% of national health expenditures. The findings highlight significant variability across countries and provide crucial insights to help policymakers to make informed decisions and allocate resources effectively to improve national strategies around surveillance, preventive and treatment strategies to control the spread of COVID-19 disease in the future.
- 24 April 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (5) , 669
Open AccessCOVID-19 Disease and Economic Burden to Healthcare Systems in Adults in Six Latin American Countries Before Nationwide Vaccination Program: Ministry of Health Database Assessment and Literature Review
The COVID-19 pandemic imposed a substantial burden on healthcare systems worldwide, yet reliable data on COVID-19 morbidity, mortality, and healthcare costs in Latin America remain limited. This study explored the disease and economic burden of COVID-19 in Argentina, Brazil, Chile, Colombia, Mexico, and Peru during the pre-vaccination period. Using national databases and a systematic review of the literature, we analyzed data on adults aged 18 and older, reporting cases, death rates, years of life lost, excess mortality, and direct medical costs. Before vaccination programs began, the average COVID-19 incidence rate was 6741 per 100,000 adults. Of these, 91% were mild cases, 7% moderate/severe, and 2% critical. Among 2,201,816 hospitalizations, 27.8% required intensive care, and 17.5% required mechanical ventilation. Excess mortality ranged from 76 to 557 per 100,000, and years of life lost spanned 241,089 to 3,312,346. Direct medical costs ranged from USD 258 million to USD 10,437 million, representing 2–5% of national health expenditures. The findings highlight significant variability across countries and provide crucial insights to help policymakers to make informed decisions and allocate resources effectively to improve national strategies around surveillance, preventive and treatment strategies to control the spread of COVID-19 disease in the future.
- Open Access
- 29 November 2023
- Published by Springer Nature in BMC Health Services Research
- Vol. 23 (1) , 1-8
Health and economic impact associated with rheumatoid arthritis discharges: a cost analysis of a two-year cohort in Mexico
Background: Rheumatoid arthritis is a highly prevalent disease. Patients undergo various medical and pharmacological treatments, which have an economic impact on hospitals. The aim of this study was to estimate the direct economic costs of Mexican Social Security Institute (IMSS) resources used to provide healthcare to adult patients with rheumatoid arthritis in 2016–2017. Methods: Data of patients aged > 18 years with Rheumatoid Arthritis (RA) were obtained from databases and public information sources to estimate the use of IMSS resources for the target population. Total costs were estimated by means of the macro-costing method, employing the diagnosis-related group (DRG). Each DRG of the IMSS was constructed with one of the diagnoses and the respective combination of clinical characteristics included in the ICD-9. This study was conducted from the national perspective of IMSS, the largest healthcare service administrator in the country. As such, it can be considered representative of the broader healthcare landscape in Mexico. Results: The total cost per year of furnishing inpatient care to RA patients was found to be $170,099,794 MXN ($9,096,245.67 USD) for 2016 and $167,039,481 MXN ($8,932,592.57 USD) for 2017, implying an enormous economic impact on the government budget for Mexican public health services. Conclusions: Our results demonstrate that the direct costs of musculoskeletal and cardiovascular surgery represented the highest costs of RA in-hospital care at IMSS (the largest health institution in Mexico) in 2016 and 2017. Further studies are needed that include the cost of drugs and other indirect costs in addition to our results to get the most accurate approximation of the cost of living with RA.
- 29 November 2023
- Published by Springer Nature in BMC Health Services Research
- Vol. 23 (1) , 1-8
Open AccessHealth and economic impact associated with rheumatoid arthritis discharges: a cost analysis of a two-year cohort in Mexico
Background: Rheumatoid arthritis is a highly prevalent disease. Patients undergo various medical and pharmacological treatments, which have an economic impact on hospitals. The aim of this study was to estimate the direct economic costs of Mexican Social Security Institute (IMSS) resources used to provide healthcare to adult patients with rheumatoid arthritis in 2016–2017. Methods: Data of patients aged > 18 years with Rheumatoid Arthritis (RA) were obtained from databases and public information sources to estimate the use of IMSS resources for the target population. Total costs were estimated by means of the macro-costing method, employing the diagnosis-related group (DRG). Each DRG of the IMSS was constructed with one of the diagnoses and the respective combination of clinical characteristics included in the ICD-9. This study was conducted from the national perspective of IMSS, the largest healthcare service administrator in the country. As such, it can be considered representative of the broader healthcare landscape in Mexico. Results: The total cost per year of furnishing inpatient care to RA patients was found to be $170,099,794 MXN ($9,096,245.67 USD) for 2016 and $167,039,481 MXN ($8,932,592.57 USD) for 2017, implying an enormous economic impact on the government budget for Mexican public health services. Conclusions: Our results demonstrate that the direct costs of musculoskeletal and cardiovascular surgery represented the highest costs of RA in-hospital care at IMSS (the largest health institution in Mexico) in 2016 and 2017. Further studies are needed that include the cost of drugs and other indirect costs in addition to our results to get the most accurate approximation of the cost of living with RA.
- Open Access
Effectiveness of COVID-19 Vaccination on Transmission: A Systematic Review
Vaccination against infectious disease affords direct protection from vaccine-induced immunity and additional indirect protection for unvaccinated persons. A systematic review was conducted to estimate the indirect effect of COVID-19 vaccination. From PubMed and Embase, 31 studies were included describing the impact of original wild-type COVID-19 vaccines on disease transmission or viral load. Overall, study results showed the effectiveness of COVID-19 vaccination against SARS-CoV-2 transmission (range 16–95%), regardless of vaccine type or number of doses. The effect was apparent, but less pronounced against omicron (range 24–95% for pre-omicron variants versus 16–31% for omicron). Results from viral load studies were supportive, showing SARS-CoV-2 infections in vaccinated individuals had higher Ct values, suggesting lower viral load, compared to infections among the unvaccinated. Based on these findings, well-timed vaccination programs may help reduce SARS-CoV-2 transmission—even in the omicron era. Whether better-matched vaccines can improve effectiveness against transmission in the omicron era needs further study.
Open AccessEffectiveness of COVID-19 Vaccination on Transmission: A Systematic Review
Vaccination against infectious disease affords direct protection from vaccine-induced immunity and additional indirect protection for unvaccinated persons. A systematic review was conducted to estimate the indirect effect of COVID-19 vaccination. From PubMed and Embase, 31 studies were included describing the impact of original wild-type COVID-19 vaccines on disease transmission or viral load. Overall, study results showed the effectiveness of COVID-19 vaccination against SARS-CoV-2 transmission (range 16–95%), regardless of vaccine type or number of doses. The effect was apparent, but less pronounced against omicron (range 24–95% for pre-omicron variants versus 16–31% for omicron). Results from viral load studies were supportive, showing SARS-CoV-2 infections in vaccinated individuals had higher Ct values, suggesting lower viral load, compared to infections among the unvaccinated. Based on these findings, well-timed vaccination programs may help reduce SARS-CoV-2 transmission—even in the omicron era. Whether better-matched vaccines can improve effectiveness against transmission in the omicron era needs further study.